In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Dealmaking Statistics, Q2 2015

A look at financing, M&A and alliance activity April–June 2015

Executive Summary

Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.

You may also be interested in...



Gene Therapy: Cures Within Reach

After rocky beginnings, there is increasing optimism about the potential for gene therapy to make an impact in rare disease. Promising data from late-stage clinical trials, improved safety, and the first Western regulatory approval of a gene therapy are now driving numerous initial public offerings, venture capital financings, and tie-ups with major pharmaceutical companies.

Deals In Depth: December 2020

Merck KGaA and Artios penned a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs. The deal could be worth close to $7bn for four-year-old Artios. AstraZeneca announced a definitive agreement to acquire public rare disease drug developer Alexion for approximately $39bn. This was 2020’s largest M&A. Financing reached $28bn in biopharma, $879m in device, and $2.4bn in diagnostics.

EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021

Coming year could feature first-time approvals in the EU for at least five gene therapies.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel